I'm curious about the Piper Jaffray analyst. His comments seem at best irresponsible and at worst market manipulation.
So I guess the 2 hours of good news that we heard this morning on the conference call/presentation are meaningless. Plus don't forget the support from the Bill and Melinda Gates Foundation (up to 89 million). This is crazy.
I'm with you as well. Particularly screwy after many days of significant declines. Time to turn the corner, right? Apparently not.
I believe I congratulated you and said have fun spending your fictional money.
Yeah, my father missed the window. He had dementia from Parkinson's Disease. Very difficult for and his family. I would have liked a chance to test the drug on him.
This from someone with a id created August 12th, 2015. Have fun with your fictional $9.5 million.
Read this and it should make sense. Key word here is inverse. "The investment seeks to replicate, net of expenses, three times the opposite (inverse) of the S&P GSCI Crude Oil Index ER. The index comprises futures contracts on a single commodity and is calculated according to the methodology of the S&P GSCI Index."
This topic has been discussed quite extensively for a long time. I suggest searching this message board for "buyout" or "buy out" or "takeover" or "take over" and you will get more than you care to read.
I will remain patient and do what I do (which is nothing except count my gains), but afterhours fireworks during and post Cramer would be fun.
Novavax ($NVAX) is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.
The candidate is a recombinant virus-like particle vaccine developed with funds from the U.S. government's Biomedical Advanced Research and Development Authority (BARDA). It was well-tolerated with no vaccine-related adverse events in a trial of 400 adults. The recombinant nature of the vaccine gives it an advantage over traditional flu vaccines, which are egg-based.
What differentiates it is that it reflects the circulating strain exactly, Greg Glenn, Novavax senior vice president of R&D, said in an interview. This could help combat strain drift, as happened this year, when the flu strains that health authorities predicted didn't match the strains that actually circulated.
"If it's known a strain change occurred … because we are recombinant, we can take it into account and manufacture (a vaccine targeting the new strain)," Glenn said. "It needs to be proven, but it is definitely a theoretical advantage."
Another advantage of the recombinant vaccine is the speed at which it can be manufactured.
"We can download the genetic sequence (or the circulating strain) from the Internet and turn it into a protein," Glenn said. With recombinant technology, he added, you can move very quickly from a lethal virus to having a vaccine against it, which is how the company is working on jabs against Ebola, pandemic flu (H7N9) and MERS.
As for next steps, Novavax will review it with its partner, BARDA, and then create a strategy to bring both its seasonal and pandemic flu vaccines toward licensure, Novavax CEO Stan Erck told FierceVaccines.
"The next step for sure will be to go to the next level with the pandemic flu vaccine, … a dose-ranging trial at the beginning of next year," Erck said. In October 2014, Novavax nabbed a fast-track designation from the FDA for its H7N9 candidate.
Competitor VaxInnate is also working on a recombinant quadrivalent seasonal flu jab, which it is testing against Sanofi's ($SNY) Fluzone Quadrivalent in Phase II.